Viatris Inc. (VTRS) is a global healthcare company with a market cap of $15.1 billion, operating across multiple regions and offering a wide range of medicines. The company’s stock has outperformed the broader market, showing a 14.6% increase over 52 weeks and a 5.1% rise YTD.

Despite beating Q3 expectations with $0.67 adjusted EPS and $3.76 billion revenue, Viatris shares fell nearly 6% due to a U.S. net loss of $128 million, driven by investment value reductions and higher taxes. Analysts expect adjusted EPS to grow 12.5% YoY to $2.32 for the fiscal year ending December 2025.

10 analysts covering VTRS rate it a “Moderate Buy,” with a more bullish configuration in recent months, including two “Strong Buy” ratings. Piper Sandler raised the price target to $12, with a mean target of $13.33, representing a 1.8% premium to current levels and a high target of $16 suggesting a 22.2% upside.

Read more at Yahoo Finance: What Are Wall Street Analysts’ Target Price for Viatris Stock?